---
layout: post
title: 盐野义制药的新冠抗病毒药丸在日本获得批准
date: 2022-11-22 19:33:04.000000000 +08:00
link: https://cn.wsj.com/amp/articles/%E7%9B%90%E9%87%8E%E4%B9%89%E5%88%B6%E8%8D%AF%E7%9A%84%E6%96%B0%E5%86%A0%E6%8A%97%E7%97%85%E6%AF%92%E8%8D%AF%E4%B8%B8%E5%9C%A8%E6%97%A5%E6%9C%AC%E8%8E%B7%E5%BE%97%E6%89%B9%E5%87%86-11669116605
categories: wsj
---

<main id="main" role="main">
<div>


</div>
<div itemprop="articleLead" data-sbId="CN-BIZ-20221122191815">
    <div>
      <div class="media-object scope-
          header
">
          <figure>
      <div>
        <img
          srcset="https://images.wsj.net/im-486140?width=540&amp;size=1.5005861664712778 540w, https://images.wsj.net/im-486140?width=620&amp;size=1.5005861664712778 620w, https://images.wsj.net/im-486140?width=639&amp;size=1.5005861664712778 639w, https://images.wsj.net/im-486140?width=860&amp;size=1.5005861664712778 860w, https://images.wsj.net/im-486140?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=1.5 1290w, https://images.wsj.net/im-486140?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=2 1720w, https://images.wsj.net/im-486140?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=3 2580w"
          src="https://images.wsj.net/im-486140?width=860&amp;height=573"
          layout="responsive"
          placeholder
          alt="">
        </img>
      </div>
      <figcaption>
        <p> 图片来源：NORIKO HAYASHI/BLOOMBERG NEWS</p>
  </figcaption>
</figure>

      </div>
    </div>
</div>
<div data-sbId="CN-BIZ-20221122191815">

<div>

  <div>
      <p> </p>
              <p><span itemprop="name">
                <a href="https://www.wsj.com/news/author/megumi-fujikawa" itemprop="url" rel="author">Megumi Fujikawa</a>
              </span></p>

  </div>
    <time>
      2022年11月22日19:30 CST 更新
    </time>
</div>

<div subscriptions-actions subscriptions-display="NOT data.noSharing">
  <div>
    <social-share type="system" width="72" height="24"
      data-param-url="https://cn.wsj.com/articles/盐野义制药的新冠抗病毒药丸在日本获得批准-11669116605">
    </social-share>
  </div>
</div>


<div subscriptions-section="content">
</div>
<div subscriptions-section="content-not-granted">
</div>



<section subscriptions-section="content">
      <p>日本厚生劳动省的一个小组批准了盐野义制药(Shionogi &amp; Co., 4507.TO)的新冠抗病毒药丸，此前该公司提供的新数据显示了该疗法的有效性，为该药物在日本上市扫清了道路。</p>
      <p>这一决定将为辉瑞公司(Pfizer Inc., PFE)的Paxlovid和默克公司(Merck & Co. Inc., MRK)的Lagevrio提供一个替代品，这两种药物已经获得紧急使用授权。盐野义表示，计划向美国食品和药物管理局(Food and Drug Administration)提出申请，以便在美国获得批准。</p>
      <p>盐野义的该药物能抑制SARS-CoV-2病毒复制所需要的酶。它与辉瑞公司的药物的机制类似。</p>
      <div></div>
</section>

</div>
      </main>
